First Patient In (FPI) is the moment a trial stops being a plan on paper and starts generating real data. It’s also one of the clearest indicators of how efficiently a sponsor or CRO can move from protocol approval to execution.
That efficiency is getting more attention from regulators, not just sponsors. The U.S. Department of Health and Human Services (HHS) recently launched Operation Trailblazer, a coordinated effort involving the FDA, NIH, NCI, NCATS, and ARPA-H. The initiative aims to reduce the time from drug identification to first-in-human Phase 1 trials by six to twelve months by cutting regulatory friction and clarifying requirements earlier in development. Its scope is mostly regulatory rather than operational, but it signals something useful: the industry’s tolerance for unnecessary delay anywhere in the development timeline is shrinking.
That makes startup efficiency worth a closer look.
Where the time actually goes
Site activation tends to get the spotlight when people talk about startup delays, but a lot of the clock runs out earlier than that.
While startup is under constant schedule pressure, EDC build is frequently started while the protocol is still evolving. As requirements change, study teams must continually update CRFs, database configurations, edit checks, and validation activities. Combined with traditional EDC build timelines that have historically taken eight to twelve weeks, those revisions can quickly extend study startup.
Layer on the coordination required across sponsors, CROs, and technology partners, and even small inefficiencies begin to compound. Individually, they may seem manageable. Together, they add up and can delay first patient in.
The new AI advantage in EDC study build
One of the biggest opportunities to accelerate study startup is rethinking how EDC is built. Database build and configuration is where AI is having the most visible impact in data management right now. Our partner, CRScube, has demonstrated AI-assisted workflows that can take a study from CRF specifications to a configured database in minutes rather than weeks, by automating the more repetitive parts of CRF and edit-check setup.
Despite the promising technology advancements, adoption can be a challenge. In conversations with study teams, most agree the technology can produce builds far faster than traditional timelines allow. Fewer are confident their internal processes, sign-off chains, and QC steps are ready to move at that speed yet. The technology is often ahead of the organization that has to use it.
This is why CRScube is taking a practical approach to AI-led EDC setup. While the long-term vision is to automate EDC builds directly from study protocols, today’s solution begins with approved CRF specifications. This approach delivers many of the speed and quality benefits of AI while fitting naturally into existing data management workflows. Teams maintain control over CRF design and quality review, while AI automates much of the repetitive EDC configuration work.
Speed and quality aren’t actually in tension
In practice, most of the time lost in study startup isn’t time spent on careful review, it’s time spent waiting; for a database build, a protocol revision cycle, a site approval, a system handoff.
Cutting that waiting time doesn’t require cutting corners. It requires giving experienced teams better tools and clearer visibility, so their judgment goes toward the decisions that need it, instead of toward manual configuration work or chasing status updates across disconnected systems.
What this means in practice
AI-led EDC setup is a key accelerator in the race to first patient in. By reducing friction across people, processes, and technology, it helps sponsors and CROs compress study startup without compromising quality.
Organizations that embrace this approach will be better positioned to accelerate startup timelines, improve operational efficiency, and ultimately bring new therapies to patients sooner.
To learn more about CRScube’s AI-led approach to study build acceleration, contact us.